Musculoskeletal Toxicity Studies

Charles River offers a fully integrated service with a multidisciplinary team of scientists, pathologists, veterinarians, and surgeons to assess the safety and efficacy of drugs and devices that have an intentional or unintentional effect on the musculoskeletal system in both short- and long-term studies. This approach allows for the comprehensive evaluation of bone, muscle, and cartilage drug efficacy and safety as well as orthobiologic applications.

Capabilities

  • Bone Toxicology
    • Dose range finding to chronic studies
    • Juvenile bone toxicology
    • Carcinogenesis studies
  • Animal Models
    • Gonadectomy- induced bone loss (osteoporosis: OVX and ORX)5/6 nephrectomy
    • TPTx (thyroparathyroidectomy)
    • Schenk (anti-catabolic agent screen)Bone defect
    • Osteoarthritis (Surgical and chemical models)
    • Rheumatoid arthritis
    • Spinal fusion
    • Fracture healing
  • Biochemical Markers of Bone and Cartilage Turnover
    • Bone formation markers
      • Osteocalcin
      • Bone-specific alkaline phosphatase
      • PINP
    • Cartilage Degradation
      • C-telopeptide (CTxII)
    • Bone resorption markers
      • C-telopeptide (CTxl)
      • N-telopeptide
      • Deoxypyridinoline
      • TRAP 5b
    • Hormone markers
      • Calcitropic
      • Reproductive
      • Metabolic
  • Advanced imaging
    • DXA
    • pQCT
    • Micro-CT
    • XtremeCT II
    • HR-pQCT
    • Digital radiography
    • Biomechanical strength testing
  • Histomorphometry